EarliPoint Evaluation
FDA-cleared autism diagnostic device using eye-tracking technology (per vendor website)
What It Does
EarliPoint Evaluation is an FDA-cleared medical device that uses advanced eye-tracking technology and AI to objectively measure a child's social visual engagement, aiding clinicians in the diagnosis and assessment of autism spectrum disorder in children aged 16 months through 7 years.
AI Features (Expert Assessment)
EarliPoint uses AI-driven analysis of eye-tracking data to quantify social visual engagement patterns — specifically how a child attends to social cues like faces, eyes, and body language in naturalistic video stimuli. The system provides objective, quantifiable biomarkers rather than relying solely on subjective behavioral observation, representing genuine clinical AI application in diagnostics.
Who Is This For?
Parents seeking early autism evaluation for their child, and clinicians looking for objective, AI-powered assessment tools to supplement traditional diagnostic methods.
Additional Notes
This is a clinical device used in professional healthcare settings, not a consumer app. According to EarliPoint's website, the system is described as an 'FDA-cleared eye-tracking technology using visual attention biomarkers for autism.' Their site includes a Provider Directory to help parents locate a clinic offering the evaluation in their area.
Pros
- ✓ FDA-cleared with rigorous clinical validation
- ✓ Provides objective, quantifiable assessment data
- ✓ Can aid in earlier detection (children as young as 16 months)
Cons
- ✗ Only available through clinical providers, not direct-to-consumer
- ✗ Cost varies by provider and insurance coverage
- ✗ Limited to children aged 16 months to 7 years